CALGARY, AB, July 2, 2025 /CNW/ - (TSX: ARX) ARC Resources Ltd. ("ARC" or the "Company") announces that it has closed its previously announced agreement...
Creator of Red Opium unveils a transformational course helping executive women reclaim confidence, set boundaries, and speak with unapologetic clarity
NEW YORK, July 1, 2025...
Creator of Red Opium unveils a transformational course helping executive women reclaim confidence, set boundaries, and speak with unapologetic clarity
NEW YORK, July 1, 2025...
OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription...
STAMFORD, Conn., June 24, 2025 /PRNewswire/ -- Seven7 is pleased to announce its co-investment with leading Nordic private equity firm Altor in the previously announced...
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- Rockcliffe Capital is pleased to announce today the initiation of equity research coverage on Wheaton Precious Metals Corp. (TSX/NYSE: WPM), the world's premier precious metals streaming company known for its top-tier asset portfolio, strong balance sheet, and robust cash flow generation.
Hey fabulous finance queens! 🌟 Let's chat about Palantir Technologies, the AI software superstar that's been turning heads and racking up wins in the...
REMARKABLY PRESERVED 1962 SHELBY 260 COBRA, ONE OF THE ORIGINAL PROTOTYPE EXAMPLES, OFFERED FROM 36 YEARS OF CHERISHED LONGTERM OWNERSHIP | COBRA JOINED BY MODERN AMERICAN AUTOMOTIVE LEGENDS: HENNESSEY VENOM GT AND THE AMERICAN PERFORMANCE COLLECTION OF DODGE AND CHEVROLET ICONS
REMARKABLY PRESERVED 1962 SHELBY 260 COBRA, ONE OF THE ORIGINAL PROTOTYPE EXAMPLES, OFFERED FROM 36 YEARS OF CHERISHED LONGTERM OWNERSHIP | COBRA JOINED BY MODERN AMERICAN AUTOMOTIVE LEGENDS: HENNESSEY VENOM GT AND THE AMERICAN PERFORMANCE COLLECTION OF DODGE AND CHEVROLET ICONS
LOS ANGELES, June 18, 2025 /PRNewswire/ -- Azazie, the leading DTC e-tailer for all things occasionwear, announces the launch of its 2025 Atelier Homecoming Collection,...
PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid’s runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀.